DE69230372D1 - Polyoxypropylen/polyoxyethylen copolymere mit verbesserter biologischer aktivität - Google Patents

Polyoxypropylen/polyoxyethylen copolymere mit verbesserter biologischer aktivität

Info

Publication number
DE69230372D1
DE69230372D1 DE69230372T DE69230372T DE69230372D1 DE 69230372 D1 DE69230372 D1 DE 69230372D1 DE 69230372 T DE69230372 T DE 69230372T DE 69230372 T DE69230372 T DE 69230372T DE 69230372 D1 DE69230372 D1 DE 69230372D1
Authority
DE
Germany
Prior art keywords
biological activity
preparations
polyoxypropylen
polyoxyethylen
copolymere
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69230372T
Other languages
English (en)
Other versions
DE69230372T2 (de
Inventor
R Emanuele
Robert Hunter
Paula Culbreth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LadRx Corp
Original Assignee
CytRx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27100911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69230372(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by CytRx Corp filed Critical CytRx Corp
Publication of DE69230372D1 publication Critical patent/DE69230372D1/de
Application granted granted Critical
Publication of DE69230372T2 publication Critical patent/DE69230372T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/04—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers only
    • C08G65/06—Cyclic ethers having no atoms other than carbon and hydrogen outside the ring
    • C08G65/08—Saturated oxiranes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C08G65/2603—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen
    • C08G65/2606—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups
    • C08G65/2609—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups containing aliphatic hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C08G65/2618—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing nitrogen
    • C08G65/2621—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing nitrogen containing amine groups
    • C08G65/2624—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing nitrogen containing amine groups containing aliphatic amine groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/30—Post-polymerisation treatment, e.g. recovery, purification, drying
DE69230372T 1991-03-19 1992-03-18 Polyoxypropylen/polyoxyethylen copolymere mit verbesserter biologischer aktivität Expired - Fee Related DE69230372T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67328991A 1991-03-19 1991-03-19
US84787492A 1992-03-13 1992-03-13
PCT/US1992/002254 WO1992016484A1 (en) 1991-03-19 1992-03-18 Polyoxypropylene/polyoxyethylene copolymers with improved biological activity

Publications (2)

Publication Number Publication Date
DE69230372D1 true DE69230372D1 (de) 2000-01-05
DE69230372T2 DE69230372T2 (de) 2000-06-15

Family

ID=27100911

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69230372T Expired - Fee Related DE69230372T2 (de) 1991-03-19 1992-03-18 Polyoxypropylen/polyoxyethylen copolymere mit verbesserter biologischer aktivität

Country Status (19)

Country Link
US (7) US5523492A (de)
EP (1) EP0576612B1 (de)
JP (1) JP2647556B2 (de)
KR (1) KR100224539B1 (de)
CN (1) CN1069741A (de)
AT (1) ATE187154T1 (de)
AU (1) AU662146B2 (de)
CA (1) CA2106474C (de)
CZ (1) CZ194693A3 (de)
DE (1) DE69230372T2 (de)
DK (1) DK0576612T3 (de)
ES (1) ES2140408T3 (de)
GR (1) GR3032726T3 (de)
HU (1) HUT67762A (de)
IE (1) IE920860A1 (de)
IL (1) IL101305A (de)
NO (1) NO307890B1 (de)
SK (1) SK100893A3 (de)
WO (1) WO1992016484A1 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674911A (en) * 1987-02-20 1997-10-07 Cytrx Corporation Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
IE920860A1 (en) * 1991-03-19 1992-09-23 Cytrx Corp Polyoxypropylene/polyoxyethylene copolymers with improved¹biological activity
US7202225B1 (en) 1993-10-15 2007-04-10 Emanuele R Martin Therapeutic delivery compositions and methods of use thereof
USRE38558E1 (en) 1991-03-19 2004-07-20 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US6933286B2 (en) 1991-03-19 2005-08-23 R. Martin Emanuele Therapeutic delivery compositions and methods of use thereof
ZA933926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US6277410B1 (en) * 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
US5488034A (en) * 1993-02-02 1996-01-30 Xoma Corporation Pharmaceutical composition comprising BPI proteins
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
DE69431959T2 (de) * 1993-10-15 2003-11-06 Cytrx Corp Therapeutische abgabesysteme und verfahren für ihre verwendung
US5932544A (en) * 1994-05-31 1999-08-03 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) compositions
EP1181937A3 (de) 1994-08-09 2004-02-04 Cytrx Corporation Nukleinsäure enthaltender Impfstoff, Impfstoff-adjuvans
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
WO1998013069A2 (en) 1996-09-09 1998-04-02 Supratek Pharma, Inc. Fluorinated copolymeric pharmaceutical adjuncts
US6942859B2 (en) 1998-03-13 2005-09-13 University Of Southern California Red blood cells covalently bound with polymers
US6312685B1 (en) 1998-03-13 2001-11-06 Timothy C. Fisher Red blood cells covalently bound with two different polyethylene glycol derivatives
WO2000021543A1 (en) * 1998-10-09 2000-04-20 Cytrx Corporation Method and composition for treating ischemia and sickle cell anemia
CN1358171A (zh) * 1999-06-08 2002-07-10 拉卓拉药物公司 包含氨基氧基的化合价平台分子
CN1434726A (zh) 2000-06-08 2003-08-06 拉卓拉药物公司 包含高分子量聚环氧乙烷的多价平台分子
EP1335953A4 (de) * 2000-06-23 2005-03-30 Merck & Co Inc Polynukleotidvakzin-adjuvanzien und formulierungen, welche kationische tenside enthalten und deren verwendungen
US6761824B2 (en) * 2000-08-17 2004-07-13 Reeve Lorraine E Process for the fractionation of polymers
US20040266983A1 (en) * 2000-08-17 2004-12-30 Reeve Lorraine E Purified polyoxyalkylene block copolymers
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20040009940A1 (en) * 2000-10-20 2004-01-15 Coleman Michael E. Gene delivery formulations and methods for treatment of ischemic conditions
ATE503463T1 (de) * 2000-10-20 2011-04-15 Vical Inc Gen-abgabeformulierungen zur behandlung ischämischer zustände
US6492881B2 (en) * 2001-01-31 2002-12-10 Compaq Information Technologies Group, L.P. Single to differential logic level interface for computer systems
EP1389121B1 (de) * 2001-04-24 2012-02-22 Purdue Research Foundation Verfahren und zusammensetzungen zur behandlung von nervengewebeverletzungen in säugetieren
EP1539122B1 (de) * 2002-07-29 2014-01-29 Transform Pharmaceuticals, Inc. Pharmazeutische wässrige 2,6-diisopropylphenol-zusammensetzungen
US6966990B2 (en) 2002-10-11 2005-11-22 Ferro Corporation Composite particles and method for preparing
CA2508281C (en) * 2002-12-23 2011-08-09 Vical Incorporated Method for producing sterile polynucleotide based medicaments
EP1578193A4 (de) * 2002-12-23 2011-06-15 Vical Inc Gefriertrocknungsverfahren für nukleinsäure-/blockcopolymer-/kationtensid-komplexe
US7083748B2 (en) * 2003-02-07 2006-08-01 Ferro Corporation Method and apparatus for continuous particle production using supercritical fluid
KR101425385B1 (ko) * 2003-03-24 2014-07-31 플루로메드, 인코포레이티드 역성 열감응 중합체를 사용하는 일시적인 색전화
US20060008531A1 (en) * 2003-05-08 2006-01-12 Ferro Corporation Method for producing solid-lipid composite drug particles
EP1663261A2 (de) * 2003-09-05 2006-06-07 Mannarsamy Balasubramanian Gereinigte polyoxypropylen/polyoxyethylen-copolymere und herstellungsverfahren dafür
JP4898447B2 (ja) 2003-10-14 2012-03-14 プルーロームド インコーポレイテッド 結石破砕術の際の腎結石破片の閉じ込め
WO2005046438A2 (en) 2003-11-06 2005-05-26 Pluromed, Inc. Internal clamp for surgical procedures
JP4521547B2 (ja) * 2004-04-15 2010-08-11 株式会社サンメディカル技術研究所 血液ポンプの流量推定装置
WO2006060723A2 (en) * 2004-12-03 2006-06-08 Vical Incorporated Methods for producing block copolymer/amphiphilic particles
ATE546147T1 (de) * 2005-02-25 2012-03-15 Univ Michigan Zusammensetzungen und verfahren zur behandlung und vorbeugung von kardiomyopathie und herzerkrankung
US20100092505A1 (en) 2005-04-05 2010-04-15 Elisabetta Bianchi Method for Shielding Functional Sites or Epitopes on Proteins
BRPI0611278A2 (pt) 2005-05-02 2010-08-31 Gen Hospital Corp tratamento de litìase sem litotripsia
US8815557B2 (en) * 2005-07-08 2014-08-26 University Of Chicago Compositions and methods for refolding of denatured proteins
US20080031847A1 (en) * 2005-12-22 2008-02-07 Pluromed, Inc. Methods and kits for treating lacerations and puncture wounds using inverse thermosensitive polymers
CN102218077A (zh) * 2006-08-01 2011-10-19 普里克萨斯医药股份有限公司 泊洛沙姆用于预防和/或治疗心力衰竭的用途
EP2061547A2 (de) 2006-09-11 2009-05-27 Pluromed, Inc. Atraumatische verstopfungsballons und -mäntel sowie verfahren zu ihrer verwendung
EP2094169A4 (de) * 2006-12-11 2016-05-04 Pluromed Inc Hämostase bei durchbluteten organen
KR20090114469A (ko) * 2007-02-22 2009-11-03 플루로메드, 인코포레이티드 수술후 생물학적 유체 흐름을 제어하기 위한 역 감열 폴리머의 용도
US8372387B2 (en) * 2007-04-05 2013-02-12 Phrixus Pharmaceuticals, Inc. Compositions and methods for the treatment of heart failure
US20110212047A1 (en) * 2007-08-10 2011-09-01 Synth Rx, Inc. Polymer Therapy for the Treatment of Chronic Microvascular Diseases
JP5298134B2 (ja) 2007-11-01 2013-09-25 パーシード セラピューティクス リミテッド ライアビリティ カンパニー 免疫抑制ポリペプチドおよび核酸
US20110052490A1 (en) * 2007-11-29 2011-03-03 Plur0Med, Inc Endoscopic mucosal resectioning using purified inverse thermosensitive polymers
US8852568B2 (en) 2007-12-17 2014-10-07 The Regents Of The University Of Michigan Compositions and methods for treating and preventing skeletal muscle deficiencies
EP2350274B1 (de) 2008-10-21 2019-01-23 The General Hospital Corporation Zelltransplantation
DE102008043343A1 (de) * 2008-10-31 2010-05-06 Evonik Goldschmidt Gmbh Silikonpolyetherblock-Copolymere mit definierter Polydispersität im Polyoxyalkylenteil und deren Verwendung als Stabilisatoren zur Herstellung von Polyurethanschäumen
WO2010072769A1 (de) 2008-12-23 2010-07-01 Basf Se Verfahren zur herstellung von polyether-blockcopolymeren
EP2490722A4 (de) 2009-10-21 2014-03-05 Otonomy Inc Modulation der geltemperatur poloxamerhaltiger formulierungen
GB201008902D0 (en) * 2010-05-27 2010-07-14 Imp Innovations Ltd Membrane enhanced polymer sythesis
EP2601299B1 (de) 2010-08-06 2019-04-24 The General Hospital Corporation D/B/A Massachusetts General Hospital System und vorrichtung zur behandlung von zellen
WO2012068079A1 (en) * 2010-11-15 2012-05-24 Adventrx Pharmaceuticals, Inc. Methods for enhancing oxygenation of jeopardized tissue
EP2685991A1 (de) 2011-03-18 2014-01-22 Baxter International Inc Peritonealdialyselösungen mit glucosepolymeren
FR2977495B1 (fr) * 2011-07-07 2014-03-07 Sanofi Sa Composition pharmaceutique et forme galenique solide a haute teneur en dronedarone et son procede de preparation
US9662345B2 (en) 2013-06-14 2017-05-30 Professional Compounding Centers Of America Antibiotic composition for inhalation and irrigation
CA2927361A1 (en) 2013-10-16 2015-04-23 Mast Therapeutics, Inc. Diuretic induced alterations of plasma volume
JP6202471B2 (ja) 2013-10-31 2017-09-27 日油株式会社 医用ポリオキシプロピレン重合体の製造方法および医用ポリオキシプロピレン／ポリオキシエチレンブロック共重合体の製造方法
WO2016007542A1 (en) 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Poloxamer therapy for heart failure
EP3747448A1 (de) * 2014-07-07 2020-12-09 LifeRaft Biosciences, Inc. Poloxamerzusammensetzung frei von langzeitzirkulierenden materialien und verfahren zur herstellung und verwendungen davon
US9757411B2 (en) 2014-07-07 2017-09-12 Aires Pharmaceuticals, Inc. Poloxamer therapy for heart failure
WO2016007562A1 (en) * 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Methods and compositions for improving hemostasis
WO2017108457A1 (en) 2015-12-22 2017-06-29 Basf Se A process for purification of polyether block copolymers
WO2018145949A1 (en) 2017-02-09 2018-08-16 Basf Se A process for purification of polyether block copolymers
KR20230088860A (ko) 2017-12-21 2023-06-20 시그마-알드리치 컴퍼니., 엘엘씨 폴록사머 조성물 및 이의 제조 및 사용 방법
GB2579707A (en) 2018-10-15 2020-07-01 Avent Inc Compositions, systems, kits, and methods for neural ablation

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2674619A (en) * 1953-10-19 1954-04-06 Wyandotte Chemicals Corp Polyoxyalkylene compounds
US2979528A (en) * 1953-10-19 1961-04-11 Wyandotte Chemicals Corp Nitrogen-containing polyoxyalkylene detergent compositions
US3022335A (en) * 1955-03-30 1962-02-20 Wyandotte Chemicals Corp Surface active polyoxyalkylene compounds having a plurality of heteric polyoxypropylene-polyoxyethylene chains
US2854378A (en) * 1955-12-08 1958-09-30 Bristol Lab Inc Tetracycline suppository
US3036118A (en) * 1957-09-11 1962-05-22 Wyandotte Chemicals Corp Mixtures of novel conjugated polyoxyethylene-polyoxypropylene compounds
US3089818A (en) * 1960-06-02 1963-05-14 Baxter Laboratories Inc Water dispersible antibiotics
US3228834A (en) * 1962-06-08 1966-01-11 Hoffmann La Roche Pharmaceutical diluent compositions
US3140232A (en) * 1962-12-19 1964-07-07 Pfizer & Co C Color stabilization of tetracycline compositions with polypropylene glycols
US3391196A (en) * 1965-08-16 1968-07-02 Wyandotte Chemicals Corp High equivalent weight hydroxy-terminated ethylene oxide-butylene oxide polyether polyols
US3740421A (en) * 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
US3450502A (en) * 1967-09-25 1969-06-17 Wyandotte Chemicals Corp Method of operating heart-lung apparatus
US3641240A (en) * 1968-09-27 1972-02-08 Wyandotte Chemicals Corp Method for the treatment of an embolus or thrombus
US3867533A (en) * 1968-12-20 1975-02-18 Basf Wyandotte Corp Preparation of aqueous gel compositions containing a water-insoluble organic ingredient
US3577522A (en) * 1969-10-10 1971-05-04 Wyandotte Chemicals Corp Methods for the treatment of shock with ethylene oxide-polypropylene glycol condensates as blood plasma substitutes
US3590125A (en) * 1969-10-10 1971-06-29 Wyandotte Chemicals Corp Physiological salt solutions of ethylene oxide-polypropylene glycol condensation products as blood plasma substitutes
US3980772A (en) * 1969-12-02 1976-09-14 Baxter Laboratories, Inc. Methods of dissolving blood clots and the like with streptokinase chemically bonded to a carbohydrate matrix
CA959759A (en) * 1970-01-15 1974-12-24 John J. Miskel Method for absorption of drugs
US3867521A (en) * 1970-08-26 1975-02-18 Scherer Corp R P Method for absorption of drugs
US3956259A (en) * 1973-01-30 1976-05-11 Baxter Laboratories, Inc. Fractionation of blood using block copolymer of ethylene oxide and polyoxypropylene polymer to recover fraction suitable for organ perfusate
US4073886A (en) * 1973-01-30 1978-02-14 Baxter Travenol Laboratories, Inc. Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3997458A (en) * 1974-04-12 1976-12-14 Deknatel, Incorporated Method of cleansing contaminated wounds and surgical scrub solutions for same
US4104455A (en) * 1975-03-25 1978-08-01 Toyo Soda Manufacturing Co., Ltd. Polymerization of monomer
US4100271A (en) * 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4195167A (en) 1976-05-28 1980-03-25 Union Carbide Corporation Gradient polymers of two or more cyclic, organic, ring-opening, addition polymerizable monomers and methods for making same
JPS545094A (en) 1977-06-09 1979-01-16 Tokyo Tanabe Co Production of pharmaceutical urokinase from contamination free human urine
DE2732929A1 (de) * 1977-07-21 1979-02-01 Bayer Ag Polyaether, verfahren zu ihrer herstellung sowie ihre verwendung als lipidabsorptionshemmer
EP0003399B1 (de) * 1978-01-27 1981-11-25 BP Chemicals Limited Verfahren zur Erhöhung der Selektivität an Essigsäure bei der Herstellung einer Mischung von C1-C3 Monocarbonsäuren durch Oxydation von Paraffinenkohlwasserstoffen
DE2808865A1 (de) * 1978-03-02 1979-09-13 Hoechst Ag Mikrobiozide mittel auf der basis von alkyl-di-guanidinium-salzen
US4275244A (en) * 1978-05-11 1981-06-23 Basf Wyandotte Corporation Linear polyalkylene ether glycols of high molecular weight
JPS5533194A (en) 1978-08-07 1980-03-08 Scholz D Thomas Stringgfastener device including tremolant
US4305922A (en) * 1978-10-04 1981-12-15 University Patents, Inc. Labeling proteins with 99m-Tc by ligand exchange
US4186253A (en) * 1978-10-10 1980-01-29 The Green Cross Corporation Perfusate for preserving organ to be transplanted and preserving method
DE2850058A1 (de) * 1978-11-18 1980-05-29 Bayer Ag Polyaether-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR2454409A1 (fr) * 1979-04-18 1980-11-14 Sovam Vehicule tracteur notamment pour avions gros porteurs
FI803077A (fi) * 1979-10-12 1981-04-13 Ciba Geigy Ag Foerfarande foer framstaellning av myramylpeptider
US4409209A (en) * 1979-10-12 1983-10-11 Ciba-Geigy Corporation Novel phosphorylmuramyl peptides and processes for the manufacture thereof
US4575484A (en) * 1980-05-05 1986-03-11 Montefiore Medical Center, Inc. Binding assay for the detection of mycobacteria
US4410660A (en) * 1980-05-05 1983-10-18 Montefiore Medical Center Binding assay for the detection of mycobacteria
US4489158A (en) * 1980-05-05 1984-12-18 Montefiore Hospital And Medical Center, Inc. Binding assay for the detection of mycobacteria
JPS578223A (en) * 1980-06-19 1982-01-16 Mitsui Petrochem Ind Ltd Production of alkylene oxide block copolymer
US4378347A (en) * 1980-06-30 1983-03-29 Franco Wayne P Composition for treating the heart for myocardial infarction
US4376118A (en) * 1980-10-06 1983-03-08 Miles Laboratories, Inc. Stable nonaqueous solution of tetracycline salt
GR78246B (de) * 1981-01-23 1984-09-26 Ciba Geigy Ag
US4395393A (en) * 1981-08-10 1983-07-26 Basf Wyandotte Corporation Artificial blood emulsifiers
US4407790A (en) * 1981-09-25 1983-10-04 Economics Laboratory, Inc. Method of controlling bloat using nonionic surfactants
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
DE3234084A1 (de) * 1982-09-14 1984-03-15 B. Braun Melsungen Ag, 3508 Melsungen Pharmazeutische zubereitungen zur behandlung von unerwuenschten verwachsungen sowie deren verwendung
SU1183112A1 (ru) * 1983-08-04 1985-10-07 Научно-Исследовательский Институт Экспериментальной И Клинической Терапии Министерства Здравоохранения Гсср Способ лечени острой ишемии миокарда
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4600652A (en) * 1985-04-01 1986-07-15 Warner-Lambert Company Permanently bonded antithrombogenic polyurethane surface
US5183687A (en) * 1985-06-18 1993-02-02 Emory University Method of treating poultry for coccidiosis
US5114708A (en) * 1985-06-18 1992-05-19 Emory University Method for stimulating growth in animals
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US5017370A (en) * 1986-05-15 1991-05-21 Emory University Improved method of performing angioplasty procedures
US5071649A (en) * 1986-05-15 1991-12-10 Emory University Method of preventing blockage in catheters
US5064643A (en) * 1986-05-15 1991-11-12 Emory University Method for treating sickle cell disease
US5041288A (en) * 1986-05-15 1991-08-20 Emory University Method of treating tissue damaged by reperfusion injury
US4897263A (en) * 1986-05-15 1990-01-30 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
DE3751907T2 (de) * 1986-05-15 1997-04-03 Univ Emory Injizierbares Arzneimittel zum Schutz vor Gewebebeschädigung durch Ischemie
US5047236A (en) * 1986-05-15 1991-09-10 Emory University Method of treating stroke
US5030448A (en) * 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US5028599A (en) * 1986-05-15 1991-07-02 Emory University Method of treating mycardial damage
US4879109A (en) * 1986-05-15 1989-11-07 Emory University Method for treating burns
US5078995A (en) * 1986-05-15 1992-01-07 Emory University Fibrionolytic composition
US4937070A (en) * 1986-05-15 1990-06-26 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5198211A (en) * 1986-05-15 1993-03-30 Emory University Method of treating myocardial damage
US4801452A (en) * 1986-05-15 1989-01-31 Hunter Robert L Fibrinolytic composition
US5250294A (en) * 1986-05-15 1993-10-05 Emory University Improved perfusion medium for transplantation of organs
US5032394A (en) * 1986-05-15 1991-07-16 Emory University Method of treating burns
US4837014A (en) * 1986-05-15 1989-06-06 Emory University An improved method of treating sickle cell anemia
US5080894A (en) * 1986-05-15 1992-01-14 Emory University Method and composition for reducing tissue damage
AU6334586A (en) * 1986-05-15 1987-12-01 Emory University Composition and method for treating a thrombus and embolus
US4997644A (en) * 1986-05-15 1991-03-05 Emory University Method of treating adult respiratory distress syndrome
US5089260A (en) * 1986-05-15 1992-02-18 Emory University Method of treating ischemic tissue
US4873083A (en) * 1986-05-15 1989-10-10 Emory University Fibrinolytic composition
US5039520A (en) * 1986-05-15 1991-08-13 Emory University Plasma extender
JP2527942B2 (ja) * 1986-09-18 1996-08-28 ティーディーケイ株式会社 磁気記録媒体
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US4764567A (en) * 1986-11-20 1988-08-16 Basf Corporation Process for the preparation of polyoxyalkylene block polyethers having enhanced properties
US5811088A (en) 1987-02-20 1998-09-22 Emory University Antiinfective compounds and methods of use
EP0305470B1 (de) * 1987-02-20 1992-11-11 Emory University Antiinfektiöse verbindungen und verfahren zur verwendung
JPH07109520B2 (ja) 1987-02-24 1995-11-22 株式会社リコー 電子写真用感光体
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
DE4014923A1 (de) * 1990-05-10 1991-11-14 Basf Ag Verfahren zur herstellung von urethan- oder urethan- und isocyanuratgruppen enthaltenden hartschaumstoffen nach dem polyisocyanat-polyadditionsverfahren und die hierfuer geeigneten polyoxyalkylen-polyole
IE920860A1 (en) * 1991-03-19 1992-09-23 Cytrx Corp Polyoxypropylene/polyoxyethylene copolymers with improved¹biological activity
US5294365A (en) * 1991-12-12 1994-03-15 Basf Corporation Hydroxypolyethers as low-foam surfactants
US5371253A (en) * 1993-12-14 1994-12-06 Arco Chemical Technology, L.P. Process for producing esterified alkoxylated monoglycerides and diglycerides

Also Published As

Publication number Publication date
USRE37285E1 (en) 2001-07-17
GR3032726T3 (en) 2000-06-30
JPH06506258A (ja) 1994-07-14
CA2106474C (en) 2004-02-10
HUT67762A (en) 1995-04-28
AU662146B2 (en) 1995-08-24
US6359014B1 (en) 2002-03-19
ES2140408T3 (es) 2000-03-01
SK100893A3 (en) 1994-04-06
KR100224539B1 (ko) 1999-10-15
US5523492A (en) 1996-06-04
NO933337L (no) 1993-11-17
US5691387A (en) 1997-11-25
USRE36665E (en) 2000-04-18
US20020183398A1 (en) 2002-12-05
US6747064B2 (en) 2004-06-08
DK0576612T3 (da) 2000-05-22
NO307890B1 (no) 2000-06-13
WO1992016484A1 (en) 1992-10-01
IL101305A0 (en) 1992-11-15
CA2106474A1 (en) 1992-09-20
HU9302628D0 (en) 1993-12-28
DE69230372T2 (de) 2000-06-15
CN1069741A (zh) 1993-03-10
US5990241A (en) 1999-11-23
ATE187154T1 (de) 1999-12-15
EP0576612A4 (de) 1994-11-09
JP2647556B2 (ja) 1997-08-27
EP0576612A1 (de) 1994-01-05
AU1773092A (en) 1992-10-21
EP0576612B1 (de) 1999-12-01
IL101305A (en) 1995-11-27
NO933337D0 (no) 1993-09-17
IE920860A1 (en) 1992-09-23
CZ194693A3 (en) 1994-03-16

Similar Documents

Publication Publication Date Title
DE69230372T2 (de) Polyoxypropylen/polyoxyethylen copolymere mit verbesserter biologischer aktivität
DK0493480T3 (da) Dehydrodidemnin B
DK0608912T3 (da) Synergistiske mikrobicide sammensætninger
ATE189263T1 (de) Auswahl von effizient ziel-rns spaltenden ribozymen
ATE281840T1 (de) Behandlung von diarrhoe
PL308122A1 (en) Viral vectors and their application in genic therapy
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
DK480284D0 (da) Sporstofmaerkede konjugater af metallothionein og maalsoegende, biologisk aktive molekyler
ATE347366T1 (de) Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen
DE3884453D1 (de) Homogene additionscopolymere von ethylen und cycloolefinmonomeren und deren herstellung.
ATE208208T1 (de) Halogenid-enthaltende insulinzubereitungen
SE9101815D0 (sv) Behandling av sjukdom foerbunden med hiv-infektioner
MY106109A (en) 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions
ITMI912456A0 (it) Ossa(tia)diazol- e triazol-oni(tioni)ad attivita' acarcida ed insetticida
RS49520B (sr) Antimikrobno aktivne smeše
MY107501A (en) Continuously magnetizing magnet.
ATE191923T1 (de) Interleukine-6 mutante mit verbesserter biologischer aktivität im vergleich zu wildtyp il-6
ES2013025A6 (es) Un metodo para preparar 24r-escimnol.
FI960839A (fi) Uusia tripeptidejä, jotka ovat käyttökelpoisia immuuni- ja CNS-terapiassa
DE69016693D1 (de) Züchtung von transformierten Mikroorganismen.
DE3769497D1 (de) Mittel zur bekaempfung von phytopathogenen mikroben.
ES2077614T3 (es) Bacillus thuringiensis, variedad donegani, y preparacion o toxina obtenida de esta, dotado de actividad insecticida frente a cleopteros.
RU93056161A (ru) Блок-сополимер полиоксипропилена и полиоксиэтилена, поверхностно-активный сополимер, способ получения нетоксичного поверхностно-активного сополимера, лекарственное средство
AU1691888A (en) Compound active in cardiovascular therapy
Cyr Self-disclosure by marital therapists and consequent spouse responses.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee